JP5147237B2 - 抗感染剤としてのイソチアゾロキノロン類および関連化合物 - Google Patents

抗感染剤としてのイソチアゾロキノロン類および関連化合物 Download PDF

Info

Publication number
JP5147237B2
JP5147237B2 JP2006523236A JP2006523236A JP5147237B2 JP 5147237 B2 JP5147237 B2 JP 5147237B2 JP 2006523236 A JP2006523236 A JP 2006523236A JP 2006523236 A JP2006523236 A JP 2006523236A JP 5147237 B2 JP5147237 B2 JP 5147237B2
Authority
JP
Japan
Prior art keywords
cyclopropyl
alkyl
fluoro
quinoline
isothiazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006523236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502275A5 (https=
JP2007502275A (ja
Inventor
バートン ジェームス ブラッドベリー
ミリンド デシュパンデ
マイケル ジョン プッチ
クイピン ワン
ジェイソン アラン ワイルズ
ヨンシェン ソン
アキヒロ ハシモト
エドライン ルシエン
Original Assignee
アキリオン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキリオン ファーマシューティカルズ,インコーポレーテッド filed Critical アキリオン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2007502275A publication Critical patent/JP2007502275A/ja
Publication of JP2007502275A5 publication Critical patent/JP2007502275A5/ja
Application granted granted Critical
Publication of JP5147237B2 publication Critical patent/JP5147237B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006523236A 2003-08-12 2004-08-04 抗感染剤としてのイソチアゾロキノロン類および関連化合物 Expired - Fee Related JP5147237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49465503P 2003-08-12 2003-08-12
US60/494,655 2003-08-12
PCT/US2004/025365 WO2005019228A1 (en) 2003-08-12 2004-08-04 Isothiazoloquinolones and related compounds as anti-infective agents

Publications (3)

Publication Number Publication Date
JP2007502275A JP2007502275A (ja) 2007-02-08
JP2007502275A5 JP2007502275A5 (https=) 2007-09-06
JP5147237B2 true JP5147237B2 (ja) 2013-02-20

Family

ID=34215887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523236A Expired - Fee Related JP5147237B2 (ja) 2003-08-12 2004-08-04 抗感染剤としてのイソチアゾロキノロン類および関連化合物

Country Status (14)

Country Link
US (2) US20050075363A1 (https=)
EP (1) EP1664062B1 (https=)
JP (1) JP5147237B2 (https=)
KR (1) KR20060069836A (https=)
CN (1) CN1867570A (https=)
AU (1) AU2004267052B2 (https=)
BR (1) BRPI0413528A (https=)
CA (1) CA2535370C (https=)
IL (1) IL173492A0 (https=)
MX (1) MXPA06001645A (https=)
NO (1) NO20060653L (https=)
NZ (1) NZ545157A (https=)
UA (1) UA84879C2 (https=)
WO (1) WO2005019228A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118605A2 (en) * 2004-11-11 2006-11-09 Achillion Pharmaceuticals, Inc. 8a, 9-dihydro-4a-h-isothiazolo[5,4-b] quinoline-3, 4-diones and related compounds as anti-infective agents
US7659399B2 (en) 2005-01-05 2010-02-09 Achillion Pharmaceuticals, Inc. 1-thia-2,4a-diaza-cyclopenta[b]napththalene-3,4-diones and related compounds as anti-infective agents
BRPI0607723A2 (pt) * 2005-02-16 2009-10-06 Achillion Pharmaceuticals Inc isotiazoloquinolonas e compostos relacionados como agentes antiinfecciosos
AU2006272571B2 (en) * 2005-07-27 2012-03-08 Achillion Pharmaceuticals, Inc. 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents
WO2008021491A2 (en) 2006-08-16 2008-02-21 Achillion Pharmaceuticals, Inc. Method for synthesis of 8-alkoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones
WO2008036420A2 (en) * 2006-09-21 2008-03-27 Achillion Pharmaceuticals, Inc. 9-(heteroaryl)-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
WO2010115184A2 (en) * 2009-04-03 2010-10-07 Achillion Pharmaceuticals, Inc. Hydroxythienoquinolones and related compounds as anti-infective agents
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
TW201726630A (zh) * 2009-10-16 2017-08-01 梅林塔療法公司 抗微生物性化合物及其製造與使用方法
WO2011047320A2 (en) * 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
CN102866153B (zh) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 前列腺炎联合检测试剂盒
KR20160070066A (ko) 2013-09-09 2016-06-17 멜린타 테라퓨틱스, 인크. 항균 화합물, 및 이의 제조 방법 및 이용 방법
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CN104530034B (zh) * 2014-12-31 2017-02-22 西南大学 喹诺酮噻唑类化合物及其制备方法和应用
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
KR101891315B1 (ko) 2017-08-01 2018-08-24 한국화학연구원 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물
KR101915550B1 (ko) 2016-10-20 2018-11-07 한국화학연구원 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
JPS62187472A (ja) * 1985-12-23 1987-08-15 アボツト ラボラトリ−ズ イソオキサゾロ−ナフチリジン、イソオキサゾロキノリン、イソチアゾロ−ナフチリジン及びイソチアゾロ−キノリン誘導体
JP2681190B2 (ja) * 1988-04-13 1997-11-26 塩野義製薬株式会社 ピリドン系抗菌剤
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
CA2001203C (en) * 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
US4945160A (en) * 1988-11-22 1990-07-31 Warner-Lambert Company Preparation of certain 7-substituted quinolones
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US20020103115A1 (en) * 2000-09-19 2002-08-01 Karl Guegler Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7678235B2 (en) * 2005-10-19 2010-03-16 Sylvan Source, Inc. Water purification system
BRPI0607723A2 (pt) * 2005-02-16 2009-10-06 Achillion Pharmaceuticals Inc isotiazoloquinolonas e compostos relacionados como agentes antiinfecciosos

Also Published As

Publication number Publication date
AU2004267052A1 (en) 2005-03-03
MXPA06001645A (es) 2006-05-12
NO20060653L (no) 2006-03-13
EP1664062B1 (en) 2013-03-13
JP2007502275A (ja) 2007-02-08
CN1867570A (zh) 2006-11-22
NZ545157A (en) 2009-03-31
WO2005019228A1 (en) 2005-03-03
US20050075363A1 (en) 2005-04-07
CA2535370A1 (en) 2005-03-03
US20110223132A1 (en) 2011-09-15
EP1664062A1 (en) 2006-06-07
CA2535370C (en) 2011-01-25
KR20060069836A (ko) 2006-06-22
BRPI0413528A (pt) 2006-10-10
AU2004267052B2 (en) 2009-02-05
UA84879C2 (ru) 2008-12-10
IL173492A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
JP5147237B2 (ja) 抗感染剤としてのイソチアゾロキノロン類および関連化合物
US20120114601A1 (en) New isothiazoloquinolones and related compounds as anti-infective agents
US20120040959A1 (en) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
US7199128B2 (en) 8-N-substituted-2H-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
US7659399B2 (en) 1-thia-2,4a-diaza-cyclopenta[b]napththalene-3,4-diones and related compounds as anti-infective agents
MX2007005731A (es) 8a, 9-dihidro-4a-h-isotiazolo [5,4-b] quinolina-3, 4-diomas y compuestos relacionados como agentes anti-infeccion.
JP2008519842A5 (https=)
HK1122024B (en) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
MX2008001344A (es) 8-metoxi-9h-isotiazolo[5,4-b]quinolin-3,4-dionas y compuestos relacionados como agentes anti-infecciosos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121127

R150 Certificate of patent or registration of utility model

Ref document number: 5147237

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees